Nucleovir

Nucleovir Therapeutics builds bespoke oncolytic viruses targeting immunologically cold tumors. The platform uses AI and wet lab loops to rationally engineer viruses for better tumor selectivity and immune activation, addressing a cancer type where virtually every conventional therapy has failed.